Compare Intel Corp (INTC) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Medpace Holdings Inc — how do they compare? Intel Corp trades at $106.67 (market cap $487.82B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Intel Corp is far larger — about 32.3× Medpace Holdings Inc's market cap, and Intel Corp pays a 2.24% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| INTC | MEDP | |
|---|---|---|
Market Cap | $487.82B | $15.08B |
Volume | 43,552,012 | — |
Sector | Technology | Technology |
52-Week High | $140.94 | $620.59 |
52-Week Low | $19.31 | $308.88 |
Enterprise Value | $500.07B | $14.55B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $105.45, up 10.95% on the day, showing strong momentum ahead of Q2 2026 earnings. The stock exhibits a bearish technical signal but has beaten EPS estimates for three consecutive quarters. Revenue remains stable around $53B, though net income turned negative in 2025. Recent news highlights optimism around data center and AI segment growth, with a new partnership with Fortinet for security chips announced on July 21, 2026.
The outlook is mixed: analyst consensus suggests modest upside to a $110.33 price target, but high valuation ratios (P/E 904.17) and negative profitability metrics pose risks. Key catalysts include Q2 earnings results and execution of the turnaround strategy under CEO Lip-Bu Tan, while competitive pressures from Nvidia and AMD remain headwinds.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
